Nebivolol is prescribed for:
- Treatment of high blood pressure
- Heart failure in some cases
- Improving cardiovascular outcomes
Unlike older beta-blockers, nebivolol also causes blood vessels to relax through nitric oxide release.
Generic Name: Nebivolol
Brand Names: Bystolic
Nebivolol is a newer generation beta-blocker with vasodilating properties, used to treat high blood pressure.
Nebivolol is prescribed for:
Unlike older beta-blockers, nebivolol also causes blood vessels to relax through nitric oxide release.
Common side effects include:
Serious side effects:
Nebivolol is a third-generation beta blocker that combines beta-1 receptor blockade with vasodilating properties. This makes it unique among beta-blockers.
Nebivolol works through:
Nebivolol may cause fewer side effects like fatigue and sexual dysfunction compared to older beta-blockers, making it a preferred choice for many patients with hypertension.
For more details, see MedlinePlus.
This medication is commonly used to treat or manage the following conditions:
Portal hypertension, an elevated pressure in the portal vein due to blockage often from cirrhosis or other pre-hepatic causes, can lead to serious complications like bleeding and ascites.
Secondary pulmonary hypertension, unlike its primary form, arises from underlying conditions such as heart/lung disease, blood clots, or connective tissue disorders, increasing lung artery pressure.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Have questions about Nebivolol? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.